Johnson & Johnson raises 2026 revenue guidance to $101.1B but shares fall 1.8% in premarket trading.
Johnson & Johnson shares declined 1.8% in premarket trading Wednesday despite surpassing Q2 earnings and revenue estimates. The company also lifted its 2026 revenue guidance to $101.1B from a prior $100.8B, alongside upward EPS revisions.
Analysts had anticipated strong results following JNJ’s recent performance, though the raised outlook exceeded consensus expectations. The prior quarter’s revenue stood at $99.1B, reflecting steady growth in pharmaceutical and medical device segments.
Premarket losses suggest investor caution despite the positive financial update, with no immediate catalyst for the pullback identified.